CSCIF (Cosciens Biopharma) Interest Expense: $-0.14 Mil (TTM As of Mar. 2026)

What is Cosciens Biopharma Interest Expense?

Cosciens Biopharma CSCIF +3.90% 60 Interest Expense is $-0.14 Mil as of Mar. 2026. GuruFocus rates CSCIF with a GF Score™ of 60/100 and a GF Value™ of $2.39 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cosciens Biopharma's interest expense for the three months ended in Mar. 2026 was $ -0.05 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.14 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cosciens Biopharma's Operating Income for the three months ended in Mar. 2026 was $ -0.73 Mil. Cosciens Biopharma's Interest Expense for the three months ended in Mar. 2026 was $ -0.05 Mil. Cosciens Biopharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cosciens Biopharma (OTCPK:CSCIF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cosciens Biopharma's Interest Expense for the three months ended in Mar. 2026 was $-0.05 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-0.73 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $1.84 Mil.

Cosciens Biopharma's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Cosciens Biopharma did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Cosciens Biopharma Interest Expense Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's Interest Expense can be seen below:

Cosciens Biopharma Interest Expense Chart

Cosciens Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-0.12

-0.14

-0.13

-0.17

Cosciens Biopharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-0.07	-0.02	-0.04	-0.03	-0.05

60GF Score

Cosciens Biopharma Inc CSCIF

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cosciens Biopharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.14 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of $-0.14 Mil mean?

Cosciens Biopharma (CSCIF) has a Interest Expense of $-0.14 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Cosciens Biopharma and its competitors.

Is Cosciens Biopharma's Interest Expense too high?

Cosciens Biopharma's current Interest Expense is $-0.14 Mil. Overall, Cosciens Biopharma has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Cosciens Biopharma's Interest Expense compare to VRTX and REGN?

Cosciens Biopharma's Interest Expense of $-0.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current Interest Expense is $-0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cosciens Biopharma stock overvalued right now?

Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.39, compared to a current price of $2.13 — trading 10.9% below its estimated fair value. The current Interest Expense is $-0.14 Mil. Cosciens Biopharma's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Interest Expense is $-0.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosciens Biopharma (CSCIF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of $2.13 is trading 10.9% below its estimated GF Value™ of $2.39. GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.

Key valuation signals for CSCIF:

Interest Expense: $-0.14 Mil
GF Value™: $2.39 vs. price of $2.13 (10.9% below fair value)
GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Industry Healthcare Biotechnology

Comparable Companies XCNQ:GLOW TSXV:MRVL XCNQ:BETR TSXV:KNE TSXV:IOT TSXV:HEM TSX:APS XCNQ:PHRM XCNQ:HEAL TSXV:XRTX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges ET8:Germany CSCI:Canada

Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3

Website https://www.cosciensbio.com

Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.

60GF Score

Get the complete analysis for CSCIF

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.13

Price

$2.39

GF Value

View CSCIF Analysis

See Interest Expense data for all stocks →